Bimekizumab
Monoclonal antibody
- 1 min read
- 3 chapters
Explore on Lably
ToursExplore Lably’s 3D toursThe most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat). Injection site reactions were also common, reported in 3% of subjects.
Bimekizumab was approved for medical use in the European Union in August 2021 and in the US in October 2023. In November 2024, bimekizumab was approved by the US Food and Drug Administration for the treatment of active moderate-to-severe hidradenitis suppurativa in adults.
Medical uses
In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.
Sign in to keep reading
2 more chapters are free with a Lably account.
Society and culture
Names
Bimekizumab is the international nonproprietary name (INN).
Research
Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab but also secukinumab (PASI 100 at week 16: 61.7% vs 48.9% in BE RADIANT) and ustekinumab (PASI 90 at week 16: 85.0% vs 49.7% in BE VIVID) for the treatment of plaque psoriasis.
The approval for the treatment of active moderate-to-severe hidradenitis suppurativa (HS) in adults was supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe HS.